Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allergovit 6-Grasses accelerated versus standard dose escalation safety trial
2017-000754-19Phase 2Completed
- Sponsor
- Allergopharma
- Start
- May 2017
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Allergovit in seasonal allergic rhinitis (SAR) (2 arms), sponsored by Allergopharma. Primary endpoint: Safety and tolerability of accelerated dose escalation. Started May 2017; status: completed.
02
Drugs
Allergovit
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on 2017-000754-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000754-19.